These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26104878)

  • 1. Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes.
    Wu T; Betty B; Downie M; Khanolkar M; Kilov G; Orr-Walker B; Senator G; Fulcher G
    Diabetes Ther; 2015 Sep; 6(3):273-87. PubMed ID: 26104878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix Regimens.
    Downie M; Kilov G; Wong J
    Diabetes Ther; 2016 Dec; 7(4):641-657. PubMed ID: 27658921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement.
    Brito M; Ligthelm RJ; Boemi M; Kumar A; Raz I; Koblik T; Gao Y; Christiansen JS
    Indian J Endocrinol Metab; 2011 Jul; 15(3):152-60. PubMed ID: 21897890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
    Giugliano D; Tracz M; Shah S; Calle-Pascual A; Mistodie C; Duarte R; Sari R; Woo V; Jiletcovici AO; Deinhard J; Wille SA; Kiljanski J
    Diabetes Care; 2014 Feb; 37(2):372-80. PubMed ID: 24170763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
    Demir T; Turan S; Unluhizarci K; Topaloglu O; Tukek T; Gogas Yavuz D
    Front Endocrinol (Lausanne); 2021; 12():616514. PubMed ID: 33776914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement.
    Unnikrishnan AG; Tibaldi J; Hadley-Brown M; Krentz AJ; Ligthelm R; Damci T; Gumprecht J; Gero L; Mu Y; Raz I
    Int J Clin Pract; 2009 Nov; 63(11):1571-7. PubMed ID: 19780866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designer insulins regimens in clinical practice--pilot multicenter Indian study.
    Joshi SR; Kalra S; Badgandi M; Rao YS; Chawla M
    J Assoc Physicians India; 2005 Sep; 53():775-9. PubMed ID: 16334621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus on Initiation and Intensification of Premix Insulin in Type 2 Diabetes Management.
    Mohan V; Kalra S; Kesavadev J; Singh AK; Kumar A; Unnikrishnan AG; Chawla R; Mukherjee JJ; Sahay RK; Kumar JS; Bhoraskar A; Asirvatham AJ; Panda JK; Zargar AH; Das AK
    J Assoc Physicians India; 2017 Apr; 65(4):59-73. PubMed ID: 28527166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Validation Survey to Assess Usage of Premix Insulins in Management of Diabetes with Respect to the Recommendations Enlisted in Indian Guidelines.
    Kalra S; Sahay R; Tiwaskar M; Priya G; Das S; Bantwal G
    J Assoc Physicians India; 2020 Jun; 68(6):20-25. PubMed ID: 32610874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations.
    Deed G; Kilov G; Dunning T; Cutfield R; Overland J; Wu T
    Diabetes Ther; 2017 Dec; 8(6):1265-1296. PubMed ID: 29116584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
    Fonseca V; Davidson J; Home P; Snyder J; Jellinger P; Dyhr Toft A; Barnett A
    Curr Med Res Opin; 2010 Jul; 26(7):1621-8. PubMed ID: 20429817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom.
    Brod M; Basse A; Markert M; Pfeiffer KM
    Diabetes Ther; 2019 Aug; 10(4):1323-1336. PubMed ID: 31127490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from Biphasic Human Insulin to Premix Insulin Analogs: A Review of the Evidence Regarding Quality of Life and Adherence to Medication in Type 2 Diabetes Mellitus.
    El Naggar N; Kalra S
    Adv Ther; 2017 Jan; 33(12):2091-2109. PubMed ID: 27739002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?".
    Ghosal S; Sinha B; Majumder A; Das AK; Singh AK; Ghoshdastidar B; Maji D; Goyal G; Mukherjee JJ; Gangopadhyay KK; John M; Chatterjee S; Jaggi S; Ray S; Majumdar S; Sharma SK
    J Assoc Physicians India; 2017 Jul; 65(7):51-62. PubMed ID: 28792170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
    Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.
    Gomez-Peralta F; Al-Ozairi E; Jude EB; Li X; Rosenstock J
    Diabetes Obes Metab; 2021 Jul; 23(7):1445-1452. PubMed ID: 33651460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.